Login to Your Account

$15M Payment Up Front

Alnylam Signs Japanese Partner for RNAi-Based RSV Program

By Tiffany Turner

Friday, June 20, 2008
Alnylam Pharmaceuticals Inc. inked its third significant deal of the year, signing an exclusive alliance agreement to develop and commercialize ALN-RSV01, its lead RNAi therapeutic for the treatment of respiratory syncytial virus (RSV) infection, with Japanese firm Kyowa Hakko Kogyo Co. Ltd. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription